Entrectinib and Lazertinib: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Entrectinib
Lazertinib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions
Interaction Deep Dive
Concomitant use of lazertinib with CYP3A4 substrates having narrow therapeutic index may increase CYP3A4 substrate with NTI exposure and may also increase risk of CYP3A4 substrates with NTI-related adverse reactions. Concomitant use of lazertinib increased midazolam (CYP3A4 substrate) Cmax by 1.4-fold and AUC by 1.5-fold. Monitor for adverse reactions associated with a CYP3A4 substrate where minimal concentration changes may lead to serious adverse reactions1.
Why it happens (mechanism)
Inhibition of CYP3A4-substrate metabolism by lazertinib
Literature reports
1 report — tap to read
a) Concomitant use of lazertinib increased midazolam (CYP3A4 substrate) Cmax by 1.4-fold and AUC by 1.5-fold 1.
Common questions
Can I take Entrectinib and Lazertinib together?
Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Always confirm with your pharmacist or prescriber before making any change.
How serious is the Entrectinib and Lazertinib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Entrectinib or Lazertinib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: LAZCLUZE™ oral tablets, lazertinib oral tablets. Janssen Biotech, Inc. (Per FDA), Horsham, PA, 2025. DailyMed
Keep reading about Entrectinib
Keep reading about Lazertinib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist